IN8bio, Inc. (INAB)
1.09
-0.05
(-4.39%)
USD |
NASDAQ |
Sep 09, 12:39
IN8bio Debt to Equity Ratio : 0.1186 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1186 |
| March 31, 2026 | 0.1033 |
| December 31, 2025 | 0.101 |
| September 30, 2025 | 0.2242 |
| June 30, 2025 | 0.2046 |
| March 31, 2025 | 0.3078 |
| December 31, 2024 | 0.3474 |
| September 30, 2024 | 0.6372 |
| June 30, 2024 | 0.433 |
| March 31, 2024 | 0.3261 |
| December 31, 2023 | 0.1962 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.2963 |
| June 30, 2023 | 0.2596 |
| March 31, 2023 | 0.3293 |
| December 31, 2022 | 0.2584 |
| September 30, 2022 | 0.1635 |
| June 30, 2022 | 0.0756 |
| March 31, 2022 | 0.069 |
| December 31, 2021 | 0.0631 |
| September 30, 2021 | 0.0596 |
| March 31, 2021 | 0.111 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 21.74M |
| Total Liabilities (Quarterly) | 3.382M |
| Shareholders Equity (Quarterly) | 18.36M |
| Current Ratio | 8.206 |
| Net Debt Paydown Yield | 3.02% |